التفاصيل البيبلوغرافية
| العنوان: |
Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers. |
| المؤلفون: |
DiSilvestro, Jessica B.1 jbdisilvestro@gmail.com, Haddad, Jessica2, Robison, Katina1, Beffa, Lindsey1, Laprise, Jessica1, Scalia-Wilbur, Jennifer1, Raker, Christina1, Clark, Melissa A.2,3, Lokich, Elizabeth1, Hofstatter, Erin4, Dalela, Disha4, Brown, Amy5, Bradford, Leslie6, Toland, Maris6, Stuckey, Ashley1 |
| المصدر: |
Journal of Women's Health (15409996). May2024, Vol. 33 Issue 5, p624-628. 5p. |
| مصطلحات موضوعية: |
*RISK assessment, *CARRIER state (Communicable diseases), *CROSS-sectional method, *BRCA genes, *EARLY detection of cancer, *OVARIAN tumors, *QUESTIONNAIRES, *FISHER exact test, *DESCRIPTIVE statistics, *ENDOSCOPIC ultrasonography, *AGE distribution, *EMAIL, *SURVEYS, *RESEARCH, *ORAL contraceptives, *PATIENT decision making, *TUMOR antigens, *GENETIC testing |
| مستخلص: |
Objective: To determine the utilization of risk-reducing strategies and screening protocols for ovarian cancer in female BRCA1/2 carriers. Methods: This study was a sub-analysis of female participants from a larger multicenter, cross-sectional survey of BRCA1/2 mutation carriers unaffected by cancer. The questionnaire was administered electronically via email at four institutions located in the northeast United States. Data were analyzed with Fisher's exact test. Results: The survey was completed by 104 female BRCA mutation carriers. BRCA subtypes included 54.3% BRCA2, 41.0% BRCA1, and 2.9% both. The age at which patients underwent genetic testing varied 21.2% were 18–24 years, 25.0% were 25–34 years, 29.8% were 35–44 years, and 24.0% were 45 years or older. Nearly, all respondents (97.1%) reported that a provider had discussed risk-reducing surgeries. Of the 79 females who underwent genetic testing before 45 years of age, 53.2% reported that a health care provider recommended taking combined oral contraceptive pills (COCs) to reduce their risk of ovarian cancer, and, of these women, 88.1% chose to use them. COCs were offered at higher rates among women who were younger at the age of genetic testing (18–24: 86%, 25–34: 62%, 35–44: 23%; p < 0.0001). Approximately half (55.8%) of the respondents reported having been offered increased screening for possible early detection of ovarian cancer, of which 81.0% chose to undergo screening. The majority utilized a combination of transvaginal ultrasound and serum CA125 measurements. There were no differences observed in screening utilization based on BRCA mutation type. Conclusion: In our cohort of female BRCA mutation carriers, risk-reducing surgery was offered to almost all women, whereas only half were offered risk-reducing medication and/or increased screening. Further investigation is needed to identify barriers to the utilization of risk-reducing strategies among this high-risk population. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
